1. Anticholinergic burden (AChB) from medications is linked to poorer cognitive performance and decreased total gray matter volume in individuals with psychosis spectrum disorders.
2. Polygenic scores (PGSs) for cognition and psychiatric disorders modify the impact of AChB on cognitive outcomes and brain structure, demonstrating significant gene-by-environment interactions.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
